CN107108625A - 螺环衍生物 - Google Patents

螺环衍生物 Download PDF

Info

Publication number
CN107108625A
CN107108625A CN201580059377.7A CN201580059377A CN107108625A CN 107108625 A CN107108625 A CN 107108625A CN 201580059377 A CN201580059377 A CN 201580059377A CN 107108625 A CN107108625 A CN 107108625A
Authority
CN
China
Prior art keywords
diazaspiro
oxa
fluorophenoxy
undecane
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580059377.7A
Other languages
English (en)
Chinese (zh)
Inventor
S·克雷莫纳西
T·卢克
T·塞梅拉罗
F·米凯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chronos Therapeutics Ltd
Original Assignee
Chronos Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chronos Therapeutics Ltd filed Critical Chronos Therapeutics Ltd
Publication of CN107108625A publication Critical patent/CN107108625A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580059377.7A 2014-09-16 2015-09-14 螺环衍生物 Pending CN107108625A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1416352.1 2014-09-16
GBGB1416352.1A GB201416352D0 (en) 2014-09-16 2014-09-16 Spirocyclic derivatives
PCT/IB2015/057030 WO2016042452A1 (en) 2014-09-16 2015-09-14 Spirocyclic derivatives

Publications (1)

Publication Number Publication Date
CN107108625A true CN107108625A (zh) 2017-08-29

Family

ID=51869695

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580059377.7A Pending CN107108625A (zh) 2014-09-16 2015-09-14 螺环衍生物

Country Status (9)

Country Link
US (1) US9908897B2 (enExample)
EP (1) EP3201195A1 (enExample)
JP (1) JP2017527631A (enExample)
CN (1) CN107108625A (enExample)
AU (1) AU2015316471A1 (enExample)
BR (1) BR112017005242A2 (enExample)
CA (1) CA2997868A1 (enExample)
GB (1) GB201416352D0 (enExample)
WO (1) WO2016042452A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108164542A (zh) * 2018-01-05 2018-06-15 天津药明康德新药开发有限公司 外消旋-9-氨基-6-氧杂-2-氮杂螺[4.5]癸烷-2-羧酸叔丁基酯的合成方法
CN112679405A (zh) * 2019-10-17 2021-04-20 南京富润凯德生物医药有限公司 一种(s)-7-氧杂-2-氮杂螺[4．5]癸烷衍生物的制备方法
WO2023046214A1 (zh) * 2021-09-22 2023-03-30 中国药科大学 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831818A (zh) * 2017-02-07 2017-06-13 上海合全药业股份有限公司 一种2‑叔丁基‑7‑甲基‑5‑氧杂‑2,8‑二氮杂螺烷‑[3,5]壬烷‑2,7‑二羧酸的制备方法
CN110520422B (zh) 2017-03-24 2023-09-05 涌永制药株式会社 新型吡啶酮羧酸衍生物或其盐
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
UA129208C2 (uk) 2019-12-19 2025-02-05 Янссен Фармацевтика Нв Заміщені спіропохідні з прямим ланцюгом
CN113200997B (zh) * 2021-05-07 2023-10-03 上海合全医药有限公司 2,5-二氧杂-8-氮杂螺[3.5]壬烷及其盐的合成方法
CA3230908A1 (en) * 2021-09-20 2023-03-23 Jose-Miguel Vela-Hernandez Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1049349A (zh) * 1989-08-10 1991-02-20 格德昂·理查德化学工厂股份公司 新的2-氧代-3，8-二氮杂螺[4，5]癸烷衍生物，含有这些衍生物的药物配方及其制备方法
EP1683797A1 (en) * 2003-11-13 2006-07-26 Ono Pharmaceutical Co., Ltd. Heterocyclic spiro compound
WO2012024397A2 (en) * 2010-08-17 2012-02-23 Albany Molecular Research, Inc. 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US6835371B1 (en) 1997-09-12 2004-12-28 David R. Elmaleh Diagnostic and therapeutic piperazine and piperidine compounds and process
JP2003519223A (ja) 1999-12-30 2003-06-17 ハー・ルンドベック・アクチエゼルスカベット フェニルピペラジニル誘導体
RU2239642C1 (ru) * 2000-08-30 2004-11-10 Ф.Хоффманн-Ля Рош Аг Селективные циклопептиды
DE60330456D1 (de) * 2002-07-05 2010-01-21 Targacept Inc N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung
KR20070043008A (ko) 2004-08-20 2007-04-24 타가셉트 인코포레이티드 중독 치료에서 ｎ-아릴 디아자스피라사이클릭 화합물의용도
EP1940406A4 (en) * 2005-10-21 2009-11-18 Merck & Co Inc POTASSIUM CHANNEL INHIBITORS
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
CA2922567A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
EP3119782B1 (en) 2014-03-17 2018-01-31 reMynd NV 2,7-diazaspiro[3.5]nonane compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1049349A (zh) * 1989-08-10 1991-02-20 格德昂·理查德化学工厂股份公司 新的2-氧代-3，8-二氮杂螺[4，5]癸烷衍生物，含有这些衍生物的药物配方及其制备方法
EP1683797A1 (en) * 2003-11-13 2006-07-26 Ono Pharmaceutical Co., Ltd. Heterocyclic spiro compound
WO2012024397A2 (en) * 2010-08-17 2012-02-23 Albany Molecular Research, Inc. 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STN REGISTRY: "CAS RN 1360173-11-0", 《STN REGISTRY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108164542A (zh) * 2018-01-05 2018-06-15 天津药明康德新药开发有限公司 外消旋-9-氨基-6-氧杂-2-氮杂螺[4.5]癸烷-2-羧酸叔丁基酯的合成方法
CN112679405A (zh) * 2019-10-17 2021-04-20 南京富润凯德生物医药有限公司 一种(s)-7-氧杂-2-氮杂螺[4．5]癸烷衍生物的制备方法
CN112679405B (zh) * 2019-10-17 2023-12-15 南京富润凯德生物医药有限公司 一种(s)-7-氧杂-2-氮杂螺[4.5]癸烷衍生物的制备方法
WO2023046214A1 (zh) * 2021-09-22 2023-03-30 中国药科大学 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用

Also Published As

Publication number Publication date
JP2017527631A (ja) 2017-09-21
US20170253615A1 (en) 2017-09-07
WO2016042452A1 (en) 2016-03-24
AU2015316471A1 (en) 2017-04-20
GB201416352D0 (en) 2014-10-29
BR112017005242A2 (pt) 2017-12-12
US9908897B2 (en) 2018-03-06
CA2997868A1 (en) 2016-03-24
EP3201195A1 (en) 2017-08-09

Similar Documents

Publication Publication Date Title
CN107108625A (zh) 螺环衍生物
AU2014334554B2 (en) Selectively substituted quinoline compounds
CN109111451B (zh) 二氢嘧啶类化合物及其在药物中的应用
CN115969853A (zh) 可用作shp2抑制剂的新型杂环衍生物
WO2023143482A1 (zh) 2-氨基嘧啶类化合物或其盐及其制备方法和用途
CN105541693A (zh) 芳杂环类衍生物及其在药物上的应用
CN107207516B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
JP2023012506A (ja) 中枢神経系に関連している疾患または病態の治療に有用であるｎ－（ヘテロ）アリール置換複素環誘導体
CN114901640A (zh) 适用于治疗血脂异常的新型化合物
TW202132288A (zh) Ｔｒｅｋ（ｔｗｉｋ相關的ｋ＋通道）通道功能的調節劑
HK40040558A (en) N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system
HK40040558B (zh) 可用於治疗与中枢神经系统有关的疾病或病症的n-(杂)芳基-取代的杂环衍生物
CA3148506A1 (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer
HK1241867A1 (en) N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system
HK1241867B (en) N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system
HK1188211A1 (zh) Cxcr4受体拮抗剂
HK1196125B (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
HK1196125A (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
HK1188211B (en) Cxcr4 receptor antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170829

WD01 Invention patent application deemed withdrawn after publication